Welcome to our dedicated page for BRII BIOSCIENCES news (Ticker: BRIBY), a resource for investors and traders seeking the latest updates and insights on BRII BIOSCIENCES stock.
Brii Biosciences Limited (BRIBY) delivers innovative therapies targeting chronic hepatitis B and infectious diseases through advanced biotherapeutic platforms. This news hub provides investors and industry stakeholders with timely updates on clinical developments, strategic partnerships, and regulatory progress.
Access authoritative reporting on key initiatives including HBV combination therapies, siRNA advancements, and global clinical trial updates. Our curated news collection ensures you stay informed about BRII-877, BRII-835, and other pipeline candidates without promotional bias.
Discover verified updates across essential categories: clinical trial results, regulatory submissions, research collaborations, and therapy development milestones. Each update is vetted for relevance to long-term therapeutic goals and shareholder value.
Bookmark this page for streamlined access to Brii Biosciences' latest advancements in functional cure research. Check regularly for objective reporting on innovations shaping the future of HBV treatment.
Brii Biosciences announced promising results from two Phase 1 studies evaluating BRII-732 and BRII-778 for HIV treatment. Both candidates showed safety and tolerability, suggesting potential for a once-weekly oral combination therapy. Data presented at IDWeek 2022 highlighted their favorable pharmacokinetic profiles, which may enhance adherence compared to daily regimens. Brii aims to advance these compounds through clinical development, addressing the needs of over 38 million people living with HIV globally.
Brii Biosciences announced the top-line results from its Phase 1 study of BRII-296, a long-acting, single-injection therapy for postpartum depression (PPD). The 600 mg dosage was shown to be safe and well-tolerated, with a favorable pharmacokinetic profile. These findings position BRII-296 as a potential one-time outpatient treatment for PPD, addressing the needs of the 900,000 individuals affected in the U.S. annually. The company plans to move forward with a Phase 2 clinical trial by the end of 2022, focusing on patient-centered development.
Brii Biosciences Limited has appointed Dr. Taiyin Yang to its Board of Directors as co-chair of the newly expanded Audit and Risk Committee, effective September 1, 2022. Dr. Yang, a seasoned expert from Gilead Sciences, brings extensive experience in product development and manufacturing. Separately, non-executive board member Dr. Axel Bouchon will depart on September 30, 2022, to pursue new opportunities but will continue as an advisor. With these changes, Brii now has a diverse board of eight directors, enhancing its governance and oversight capabilities.
Brii Biosciences Limited has strengthened its global leadership team in preparation for strategic growth. The company has launched its long-acting COVID-19 therapy in China, marking a significant transition to a commercial stage. Its pipeline includes over 10 innovative candidates targeting HBV, CNS, HIV, and MDR/XDR infections. Financially, the company reported a total comprehensive expense reduction of 92.5%, while R&D expenses surged by 64% to RMB258.5 million. With ample funds to support operations through 2025, Brii Bio is poised for significant advancements in its clinical programs.
Brii Biosciences has appointed Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System (CNS) Diseases Therapy Area Head. Both leaders bring extensive experience in biotech and pharmaceutical development. Dr. de Groot has over 20 years of experience in global operations and clinical development, while Dr. Skuban has 25 years in R&D, focusing on CNS diseases. The leadership changes are aimed at strengthening Brii Bio's capabilities in addressing significant health challenges, particularly in CNS and mental health therapies.
Brii Biosciences announced that its COVID-19 therapy, the amubarvimab/romlusevimab combination, retains neutralizing activity against new Omicron subvariants BA.4/5 and BA.2.12.1. Results from independent lab studies indicate that serum concentrations exceed the levels needed for effective neutralization. The combination therapy is currently available in China and under FDA review for Emergency Use Authorization in the U.S. It demonstrated an 80% reduction in hospitalization and mortality risks among treated patients in a Phase 3 clinical trial.
Brii Biosciences has partnered with China Resources Pharmaceutical Commercial Group to enhance the distribution and access of their COVID-19 treatment, amubarvimab/romlusevimab, in China. This combination therapy is the first locally-approved SARS-CoV-2 treatment in the country, gaining market approval from the NMPA on December 8, 2021, and was launched commercially on July 7, 2022. The partnership aims to secure timely drug supply and explore novel access opportunities amid the ongoing pandemic.
Brii Biosciences Limited has appointed Dr. Susannah Cantrell as Chief Business Officer to enhance its global leadership team. With over 20 years of experience in the healthcare and biotechnology sectors, Dr. Cantrell will play a pivotal role in driving the company's growth in public health-inspired clinical programs. Previously, she held top positions at Second Genome and Tricida, leading international operations and commercial strategies. This strategic hire aims to strengthen Brii Bio's capabilities as it develops innovative therapies for infectious diseases and CNS health challenges.
Brii Biosciences Limited announced the commercial launch of the amubarvimab/romlusevimab combination therapy for COVID-19 in China, following its regulatory approval from the National Medical Products Administration (NMPA) in December 2021. This therapy, designed for patients at high risk for severe disease, demonstrates an 80% reduction in hospitalization and death based on clinical data. With the first commercial batch now available, Brii Bio emphasizes its commitment to tackling public health challenges and ensuring access to this innovative treatment.
Brii Biosciences has acquired exclusive development and commercialization rights for VIR-3434 (BRII-877) in Greater China. This strategic move enhances its clinical pipeline targeting Hepatitis B virus (HBV) and enables diverse combination treatment options. VIR-3434 is a monoclonal antibody currently in Phase 2 development. Brii's partnership with Vir Biotechnology strengthens its HBV initiatives as they explore various treatment combinations. The agreement includes milestone and royalty payments based on net sales, with rates ranging from 15% to 25%.
